Related Experiment Video
Updated: Jun 14, 2026
06:46
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
Three cases of synchronous solid tumor and multiple myeloma
Sang Hoon Ji1, Joon Oh Park, Jeeyun Lee
1Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Cancer Research and Treatment
|April 7, 2010
Summary
This study reports three cases of multiple myeloma occurring simultaneously with solid tumors. Early-stage multiple myeloma patients with solid tumors were treated for the solid tumor, with mixed survival outcomes.
Area of Science:
- Oncology
- Hematology
- Cancer Research
Background:
- The relationship between multiple myeloma and secondary solid tumors is not definitively established.
- Existing literature presents conflicting findings regarding an increased risk of secondary solid neoplasms in multiple myeloma patients.
Purpose of the Study:
- To report clinical courses and treatment outcomes of three patients with synchronous multiple myeloma and solid tumors.
- To discuss the management strategy for solid tumors in the context of early-stage multiple myeloma.
Main Methods:
- Case series reporting three patients with multiple myeloma and concurrent solid tumors.
- Treatment decisions based on Durie-Salmon stage I multiple myeloma and the primary solid tumor.
- Analysis of clinical courses and treatment results.
Main Results:
- Three cases presented: small cell lung carcinoma, colon adenocarcinoma, and pyriform sinus squamous carcinoma, all with stage I multiple myeloma.
- Solid tumors were prioritized for treatment due to the generally better prognosis of early-stage multiple myeloma.
- Two patients succumbed to their solid tumors; one patient remains alive.
Conclusions:
- Synchronous occurrence of multiple myeloma and solid tumors presents unique management challenges.
- Prioritizing treatment of the solid tumor may be a viable strategy in early-stage multiple myeloma.
- Outcomes are variable, highlighting the need for further investigation into this association.
Related Concept Videos
02:21Cancers Originate from Somatic Mutations in a Single Cell
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
02:21Cancers Originate from Somatic Mutations in a Single Cell
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
01:03Rous Sarcoma Virus (RSV) and Cancer
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
01:03Rous Sarcoma Virus (RSV) and Cancer
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...